Cytek Biosciences Inc. has unveiled the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that enhances the capabilities of their flagship Cytek Aurora system. This latest innovation integrates high-throughput and automation capabilities, allowing for improved sample throughput and data harmonization. The Cytek Aurora Evo system is designed to provide unmatched performance, reliability, and ease of use, enabling researchers to conduct large multicolor experiments without compromising data quality. The system's ability to resolve both small particles and large cells on a single instrument broadens its application range, making it a powerful tool for advancing immunology research and single-cell analysis. With over 2,600 peer-reviewed publications citing the use of Cytek's Full Spectrum Profiling™ systems, the company continues to set new standards in spectral flow cytometry, enhancing the understanding of cell biology, immunology, oncology, and targeted therapeutic methodologies. The public debut of the Cytek Aurora Evo system is scheduled for CYTO 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.